4.39
+0.2(+4.77%)
Currency In USD
| Previous Close | 4.19 |
| Open | 4.33 |
| Day High | 4.57 |
| Day Low | 4.14 |
| 52-Week High | 12.36 |
| 52-Week Low | 3.79 |
| Volume | 26.99M |
| Average Volume | 24.85M |
| Market Cap | 1.73B |
| PE | -2.44 |
| EPS | -1.8 |
| Moving Average 50 Days | 5.8 |
| Moving Average 200 Days | 6.76 |
| Change | 0.2 |
If you invested $1000 in Recursion Pharmaceuticals, Inc. (RXRX) since IPO date, it would be worth $140.26 as of May 09, 2025 at a share price of $4.39. Whereas If you bought $1000 worth of Recursion Pharmaceuticals, Inc. (RXRX) shares 3 years ago, it would be worth $789.57 as of May 09, 2025 at a share price of $4.39.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Recursion to Participate in Upcoming Investor Conferences
GlobeNewswire Inc.
May 06, 2025 12:00 PM GMT
Salt Lake City, May 06, 2025 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, announced today its participation in the following upcoming investor conferences: Ban
Preliminary Phase 1b/2 Data for REC-4881 in Familial Adenomatous Polyposis (FAP) Demonstrates Reduced Polyp Burden
GlobeNewswire Inc.
May 04, 2025 4:45 PM GMT
In the Phase 2 open-label study, REC-4881 (4 mg QD) led to a median 43% reduction (n=6 patients) in polyp burden at the Week 13 assessment at time of data cutoff.Five of six patients (83%) experienced reductions in polyp burden ranging from 31% to 82
Recursion to Report First Quarter 2025 Business Updates and Financial Results on May 5th
GlobeNewswire Inc.
Apr 28, 2025 12:27 PM GMT
Company to host public (L)earnings call on May 5th at 8:00 am ET / 6:00 am MT / 1:00 pm GMTSalt Lake City, UT, April 28, 2025 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX), a leading clinical stage TechBio company decoding biology to radically impro